エピソード

  • Middle Meningeal Artery Embolization for Chronic SDH: STEM trial
    2026/09/01

    In this episode, we review the evidence on middle meningeal artery embolization for chronic subdural hematoma, with a deep dive into the STEM trial and a brief overview of other key studies. Alongside a critical appraisal of the clinical trials, we also include a short methods segment on stratification in the context of randomization.

    Our podcast is available on Apple, Spotify, and YouTube. If you are listening on Apple or Spotify, please note that the YouTube version includes images and text overlays that may further aid understanding of the trials discussed.

    If you have been enjoying our content, please like, comment, subscribe, and share!

    続きを読む 一部表示
    31 分
  • LOGICAL
    2026/08/08

    In this episode, we review the LOGICAL trial, which compared conservative versus liberal oxygenation targets in patients admitted to the ICU following cardiac arrest. We discuss the underlying rationale, summarize prior evidence, and examine the trial in detail. We also include a methods segment on response-adaptive randomization, before concluding with a discussion of the study’s strengths and limitations.

    Our podcast is available on Apple, Spotify, and YouTube.

    If you enjoy our content, please like, comment, and subscribe—it really helps us reach a wider audience. Thank you!

    続きを読む 一部表示
    38 分
  • SODa-BIC
    2026/07/09

    In this episode, we break down the recently published SODa-BIC trial, exploring the role of IV sodium bicarbonate in critically ill patients with metabolic acidemia. We walk through the rationale, prior evidence, PICO, results, and our key critiques and takeaways. We also include a short methods segment on adaptive sample size re-estimation.

    You can also find us on Apple Podcasts and Spotify.

    続きを読む 一部表示
    41 分
  • ARISE Fluids
    2026/06/23

    In this episode, we review the recently published ARISE-Fluids trial, which compared a restrictive fluid strategy with early vasopressor use against a more liberal fluid approach with delayed vasopressors. We place the trial in context, discuss the prior evidence, and unpack the key findings. We also use the study as a springboard to introduce “time-to-event” outcomes, before reflecting on the trial’s strengths and limitations.

    Our podcast is available on Apple, Spotify, and YouTube.

    You can also explore our methods blog at: ccmevidence.blog

    続きを読む 一部表示
    34 分
  • Beyond the Data: FAST
    2026/06/02

    In this 2nd episode of BTD, we speak with Dr. Nandini Sethuraman, Chief of Microbiology at the Apollo Central Reference Laboratory in Chennai. We discuss microbiology lab workflows, the different methods involved in species identification and susceptibility testing, common pitfalls, and also her take on the FAST trial!

    続きを読む 一部表示
    27 分
  • The FAST trial: Rapid vs. Standard AST
    2026/06/02

    In this episode, we discuss the FAST trial that compared a new and rapid antibiotic susceptibility test to standard practice. We discuss the rationale, trial design, the DOOR outcome framework and its analytical approach, and the limitations.

    続きを読む 一部表示
    36 分
  • TIGRIS trial
    2026/05/08

    In this episode, we discuss the recently published Tigris trial, which evaluated the role of Polymyxin B hemoadsorption in patients with septic shock. We explore the trial’s rationale, trace the evolution of evidence in this area, examine its analytical approach (Bayesian vs. frequentist), and unpack the results. We also discuss the study’s strengths and limitations, and highlight the key takeaways.

    続きを読む 一部表示
    46 分
  • Beyond the Data: SOHO
    2026/04/17

    We’re excited to introduce Beyond the Data (BTD), a new CRITKNOW series where we invite expert clinicians and researchers to share their insights and interpret results beyond the numbers.

    In this first episode, we’re honoured to host Prof. Ram E Rajagopalan, a highly respected senior clinician, who shares his perspectives on the evolution of HFNC use, the SOHO trial, and much more.

    続きを読む 一部表示
    17 分